Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Overall emotional well‐being/mental health change ‐ up to 12 weeks' · Cancer survivors who have completed active cancer treatment Exercise interventions on health‐related quality of life for cancer survivors (2012) · Cochrane | no estimate extracted | 8 studies · 632 participants | Low |
Intervention NR Overall fatigue change ‐ Up to 12 weeks' · Cancer survivors who have completed active cancer treatment Exercise interventions on health‐related quality of life for cancer survivors (2012) · Cochrane | no estimate extracted | 10 studies · 745 participants | Moderate |
Intervention NR Overall fatigue change ‐ More than 12 weeks less than 6 months' · Cancer survivors who have completed active cancer treatment Exercise interventions on health‐related quality of life for cancer survivors (2012) · Cochrane | no estimate extracted | 3 studies · 246 participants | Low |
Intervention NR Overall pain · Cancer survivors who have completed active cancer treatment Exercise interventions on health‐related quality of life for cancer survivors (2012) · Cochrane | no estimate extracted | 4 studies · 289 participants | Moderate |
Intervention NR Overall sexuality change ‐ 6 months' · Cancer survivors who have completed active cancer treatment Exercise interventions on health‐related quality of life for cancer survivors (2012) · Cochrane | no estimate extracted | 2 studies · 193 participants | Moderate |
Intervention NR Overall sleep disturbance · Cancer survivors who have completed active cancer treatment Exercise interventions on health‐related quality of life for cancer survivors (2012) · Cochrane | no estimate extracted | 8 studies · 438 participants | Moderate |
Intervention NR Death within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA) Radiotherapy and chemoradiation after surgery for early cervical cancer (2012) · Cochrane | RR 0.84 [0.3, 2.36] | 2 studies · 397 participants | Moderate |
Intervention NR Disease progression within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA) Radiotherapy and chemoradiation after surgery for early cervical cancer (2012) · Cochrane | RR 0.58 [0.37, 0.91] | 2 studies · 397 participants | Moderate |
Intervention NR Haematological adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA) Radiotherapy and chemoradiation after surgery for early cervical cancer (2012) · Cochrane | RR 2.38 [0.63, 9.05] | 2 studies · 388 participants | Moderate |
Intervention NR Gastrointestinal adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA) Radiotherapy and chemoradiation after surgery for early cervical cancer (2012) · Cochrane | RR 7.32 [0.91, 58.82] | 2 studies · 388 participants | Moderate |
Intervention NR Genitourinary adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA) Radiotherapy and chemoradiation after surgery for early cervical cancer (2012) · Cochrane | RR 2.12 [0.54, 8.37] | 2 studies · 388 participants | Moderate |
Intervention NR Overall QoL change score ‐ up to 12 weeks' · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 11 studies · 806 participants | Very low |
Intervention NR Overall physical function change score ‐ 6 months' · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 4 studies · 305 participants | Very low |
Intervention NR Overall role function change score ‐ up to 12 weeks' · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 7 studies · 437 participants | Very low |
Intervention NR Overall role function · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 15 studies · 1100 participants | Low |
Intervention NR Overall social function change score ‐ up to 12 weeks' · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 5 studies · 378 participants | Very low |
Intervention NR Overall social function · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 16 studies · 1164 participants | Low |
Intervention NR Overall QoL · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 20 studies · 1166 participants | Very low |
Intervention NR Overall anxiety · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 12 studies · 1010 participants | Very low |
Intervention NR Overall anxiety · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 3 studies · 286 participants | Low |
Intervention NR Overall depression · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 15 studies · 1250 participants | Very low |
Intervention NR Overall depression · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 4 studies · 452 participants | Low |
Intervention NR Overall fatigue change score ‐ up to 12 weeks' · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 12 studies · 971 participants | Very low |
Intervention NR Overall fatigue · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 23 studies · 1721 participants | Very low |
Intervention NR Overall physical function change score ‐ up to 12 weeks' · people who are undergoing active treatment for cancer Exercise interventions on health‐related quality of life for people with cancer during active treatment (2012) · Cochrane | no estimate extracted | 8 studies · 540 participants | Very low |
Primary Groin Radiotherapy vs Primary Groin Surgery Groin recurrence · patients with Early Vulvar Cancer Primary groin irradiation versus primary groin surgery for early vulvar cancer (2011) · Cochrane | RR 10.21 [0.59, 175.78] | 1 study · 52 participants | Low |
Primary Groin Radiotherapy vs Primary Groin Surgery Disease specific mortality · patients with Early Vulvar Cancer Primary groin irradiation versus primary groin surgery for early vulvar cancer (2011) · Cochrane | RR 3.7 [0.87, 15.8] | 1 study · 52 participants | Low |
Topotecon+Carboplatin+Paclitaxel vs Carboplatin+Paclitaxel Overall Survivalclinical observation · patients with ovarian cancer Topotecan for ovarian cancer (2008) · Cochrane | HR 1.02 [0.97, 1.06] | 2 studies · 1998 participants | High |
Topotecon vs Topotecon+thalidomide Overall response · patients with EOC Topotecan for ovarian cancer (2008) · Cochrane | RR 0.47 [0.23, 0.99] | 1 study · 75 participants | Low |
Topotecan vs treosulfan Overall survival · patients with EOC Topotecan for ovarian cancer (2008) · Cochrane | no estimate extracted | 1 study · 274 participants | High |
Topotecan vs treosulfan Progression free survival · patients with EOC Topotecan for ovarian cancer (2008) · Cochrane | no estimate extracted | 1 study · 274 participants | High |
Topotecan vs treosulfan Response to treatment · patients with EOC Topotecan for ovarian cancer (2008) · Cochrane | RR 1.76 [1.06, 2.94] | 1 study · 274 participants | Moderate |
Topotecon+Carboplatin+Paclitaxel vs Carboplatin+Paclitaxel Progress free survival · patients with ovarian cancer Topotecan for ovarian cancer (2008) · Cochrane | HR 1.03 [1.03, 1.03] | 2 studies · 1998 participants | Low |
Topotecon vs PLD Survival Hazard Ratio (platium‐sensitive) · patients with EOC Topotecan for ovarian cancer (2008) · Cochrane | no estimate extracted | 1 study · 220 participants | Moderate |
Topotecon vs PLD Survival Hazard Ratio (Platium‐resistant) · patients with EOC Topotecan for ovarian cancer (2008) · Cochrane | RR 0.69 [0.35, 1.38] | 1 study · 255 participants | Low |
Topotecon vs PLD Progression free survival (platium‐sensitive) · patients with EOC Topotecan for ovarian cancer (2008) · Cochrane | no estimate extracted | 1 study · 220 participants | Moderate |
Topotecon vs PLD Progression free survival (platium‐resistant) · patients with EOC Topotecan for ovarian cancer (2008) · Cochrane | no estimate extracted | 1 study · 220 participants | Moderate |
Topotecon vs paclitaxel SurvivalScale from: 1 to 226.3. · patients with EOC Topotecan for ovarian cancer (2008) · Cochrane | no estimate extracted | 1 study · 226 participants | High |
Topotecon vs paclitaxel Time to progressionScale from: 1 to 137.3. · patients with EOC Topotecan for ovarian cancer (2008) · Cochrane | no estimate extracted | 1 study · 226 participants | High |
Topotecon vs Topotecon+thalidomide Progreesion free survival · patients with EOC Topotecan for ovarian cancer (2008) · Cochrane | no estimate extracted | 1 study · 73 participants | High |